Antibacterial activity of the new glycopeptide antibiotic SKF104662.
AUTOR(ES)
Jorgensen, J H
RESUMO
The inhibitory activity of the new glycopeptide antibiotic SKF104662 was generally equivalent (+/- 1 concentration increment) to the activities of vancomycin, teicoplanin, and daptomycin against selected gram-positive bacteria. However, SKF104662 demonstrated greater activity against Staphylococcus epidermidis and S. haemolyticus than did teicoplanin and was more active than the other drugs against Clostridium difficile isolates. SKF104662 possessed bactericidal activity quite similar to that of vancomycin against selected isolates of Staphylococcus, Streptococcus, and Enterococcus species.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=172478Documentos Relacionados
- In vitro activity of SK&F 104662, a new glycopeptide antibiotic.
- In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
- Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.
- A40926, a new glycopeptide antibiotic with anti-Neisseria activity.
- In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.
